16. June 2021 | 11:59 CET
Barrick Gold, Triumph Gold, Bayer - is a golden summer coming?
An old stock market adage says: Sell in May and go away. In German: Sell your positions; in summer, the market will consolidate. There was a slight correction at the beginning of May, but the DAX has been climbing since then. It is currently trying to reach the 16,000 point mark. The price of gold recently traded above USD 1,900 for the first time again, which can certainly be understood as a sign that investors want to secure their money from inflation. While the US Federal Reserve emphasized that it does not want to take any countermeasures for the time being, the US Treasury Secretary Yellen recently surprised with the statement that higher interest rates would be good for the United States. It remains exciting. There is the possibility of a golden summer on the markets.
time to read:
2 minutes
by
Armin Schulz
ISIN:
CA0679011084 , CA8968121043 , DE000BAY0017
"[...] In our experience, the local communities are supportive and friendly. [...]" Steve Cope, President, CEO and Director, Silver Viper
Author
Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
Barrick Gold - Good entry opportunity
Following the solid quarterly results, which added USD 500 million to the coffers, management expects the 2021 guidance to be achieved. In addition, CEO Bristow confirmed that the Porgera gold mine in Papua New Guinea could resume production this year. The government has since agreed to renew the mining license, which brings an almost year-long dispute to an end.
The Company should also benefit from the high commodity prices for gold and copper; these should become apparent in the upcoming quarterly figures. Primarily due to electrification, the copper price is expected to rise further. Gold is supported by a weakening USD, and also, the crash in cryptocurrencies should have made some investors rethink - these investors are now more likely to invest in gold again.
Currently, the stock stands at about CAD 28, has consolidated about 9% from its last high and offers a first entry opportunity. Considering that the stock was trading at CAD 40 at gold's high last year and gold is on its way to new highs, you can see the potential. The dividend, which is over 3% this year, also makes the stock quite attractive.
Triumph Gold - Facing new exciting news
Triumph Gold's main project is called Freegold-Mountain and is an area where gold and copper have been proven. It is located within the Dawson Range in Yukon, surrounded by large mines and major gold producers such as Rio Tinto and Newmont, which own 12% of Triumph Gold. For the past year or so, Brian Bower has been the lead director and has built a technical team. An operations office was opened in Whitehorse in late April.
The technical team has processed all historical data from 145,000 meters of drilling and samples, conducted a 3D magnetic survey, and analyzed all data in conjunction with Minerva Geosciences. This Company works with artificial intelligence algorithms. The results are not yet published; however, the Big Creek project was acquired in March based on the evaluations.
The Company has 2 million ounces of gold and copper. The current drill program was done outside this area and offers significant opportunities if additional deposits are located. The next drill area has also been defined. The CEO expects significantly more than the 2 million ounces. Since mid-June, the stock has already risen by almost 50%, but there is no end in sight, especially as the Company is also a potential takeover candidate.
Bayer - With a strong medical division
Monday, a stake of more than 5% was reported by Goldman Sachs. This shows that Bayer is again an exciting investment. The medical division reported some interesting news, including acquiring two US companies to strengthen the oncology portfolio. The acquisition gives Bayer exclusive rights to a therapy for prostate cancer.
BlueRock Therapeutics, a Group subsidiary, started clinical testing phase I for a Parkinson's drug. While there are several pieces of good news in the medical area, the takeover of Monsanto and the associated legal disputes hang over the Company like the sword of Damocles. On the positive side, demand in the agricultural sector is currently increasing.
The share has been moving sideways since the beginning of February and has not yet broken out above the EUR 58 mark. The dividend yield of around 5% certainly speaks in favor of an investment, and Bayer is also broadly positioned. There are also repeated rumors of a spin-off from Monsanto to take away this uncertainty from the share. In the long term, you cannot go far wrong with Bayer and its dividend.
